ProTrials Research teams up with Calithera for early trial help

Californian CRO ProTrials Research has been picked by fellow CA-based cancer biotech Calithera Biosciences ($CALA) to help it run an early-stage trial for its oncology candidate.

Under the deal, financial terms of which were not shared, ProTrials will deliver clinical trial development support for Calithera’s first-in-class inhibitor CB-839 program, which targets glutaminase, an enzyme found in tumor metabolism.

The candidate is currently in Phase I testing with a focus on certain types of breast and kidney cancers.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We are extremely pleased that Calithera has selected ProTrials to support research into CB-839,” said Jodi Andrews, co-founder and co-CEO of ProTrials.

“We recognize the potential of CB-839 to become an important therapeutic agent for the treatment of cancer, and look forward to applying our expertise to support Calithera's development of this first-in-class investigational compound.”

ProTrials works across a number of therapy areas and through Phases I-IV, and notes among its successfully finished trials a Phase III study for an AIDS vaccine; a potential small molecule drug for prostate cancer; and an oral medication for Alzheimer’s disease.

Calithera meanwhile just yesterday announced that the FDA has accepted its IND app for its investigational drug CB-1158 for the treatment of solid tumors. CB-1158, also a first-in-class drug, works as an orally available small molecule inhibitor of the enzyme arginase. 

- check out the release

Read more on

Suggested Articles

PPD is working with Cancer Treatment Centers of America to speed up enrollment into cancer studies.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.